SCHEMBL4867111

SCHEMBL4867111

COc1ccc(OC)c(C2=NNC(=O)C2=NNc2ccc(C)c(-c3cccnc3)c2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.42
CYP11B2 P19099 1/20 0.42
ALDH1A1 P00352 6/20 0.40
KDM4E B2RXH2 3/20 0.40
HPGD P15428 2/20 0.40
CYP1A2 P05177 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
HTR2B P41595 1/20 0.40
HSD17B10 Q99714 1/20 0.40
ABL1 P00519 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
NPC1 O15118 1/20 0.40
ALPL P05186 2/20 0.39
PDE4B Q07343 1/20 0.39
CTSD P07339 1/20 0.38
BACE1 P56817 1/20 0.38
BACE2 Q9Y5Z0 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4867109 1.00 CYP11B1 (0.42) CYP11B1CYP11B2ALDH1A1KDM4EHPGD
SCHEMBL4864163 0.86 EGFR (0.43) ALDH1A1KDM4ECYP1A2HTR2AHTR2C
SCHEMBL4864178 0.86 EGFR (0.43) ALDH1A1KDM4ECYP1A2HTR2AHTR2C
SCHEMBL4857877 0.86 TUBB4A (0.37) ALDH1A1KDM4EHSD17B10NPSR1ALPL
SCHEMBL4857883 0.86 TUBB4A (0.37) ALDH1A1KDM4EHSD17B10NPSR1ALPL
SCHEMBL4866935 0.85 GAA (0.36) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL4866929 0.85 GAA (0.36) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL4859340 0.85 MEN1 (0.38) KDM4EALPLMEN1KMT2AL3MBTL1
SCHEMBL4859338 0.85 MEN1 (0.38) KDM4EALPLMEN1KMT2AL3MBTL1
SCHEMBL4862413 0.85 KIT (0.41) ALDH1A1KDM4EHPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7452873-B2 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-18 US disclosed
US-20050222237-A1 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2005-10-06 US disclosed
US-6916798-B2 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-07-12 US disclosed
US-20040024040-A1 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2004-02-05 US disclosed
WO-2003011287-A1 PYRAZOLON DERIVATIVES AS INHIBITORS OF GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2003-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024040-A1 Inhibitors of GSK-3 and uses thereof GSK3B, AURKC, GSK3A CYP11B1 935/4885CYP11B2 861/4885ALDH1A1 3536/4885
US-20050222237-A1 Inhibitors of GSK-3 and uses thereof GSK3B, AURKC, GSK3A CYP11B1 935/4885CYP11B2 861/4885ALDH1A1 3536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.